FOQUEST™ has now been included on the Saskatchewan formulary as an Exceptional Drug Status (EDS) benefit as of March 2022 with the criteria: “For the treatment of Attention Deficit Hyperactivity Disorder (ADHD)”.
Learn more about the eligibility criteria for reimbursement of FOQUEST™ in Saskatchewan. (page 2.).